FDA Grants Orphan Drug Designation | 03-Mar-2025 | 12:05 | RNS |
Notice of Annual General Meeting | 28-Feb-2025 | 12:00 | RNS |
Positive EMA Opinion on Orphan Drug Designation | 27-Feb-2025 | 07:30 | RNS |
Annual Report 2024 published | 27-Feb-2025 | 07:15 | RNS |
Financial Statement 1 January to 31 December 2024 | 27-Feb-2025 | 07:00 | RNS |
Notice of Financial Statement and Annual Report | 19-Feb-2025 | 10:00 | RNS |
Holding(s) in Company | 14-Feb-2025 | 12:00 | RNS |
Change of Broker | 11-Feb-2025 | 07:30 | RNS |
Holding(s) in Company | 06-Feb-2025 | 15:00 | RNS |
Results of Oversubscribed Placing | 06-Feb-2025 | 07:00 | RNS |
Proposed Issue and Placing | 05-Feb-2025 | 16:30 | RNS |
Faron’s Financial Calendar for 2025 | 13-Dec-2024 | 07:00 | RNS |
Positive Phase 2 Interim Results from BEXMAB Trial | 27-Nov-2024 | 07:00 | RNS |
Shareholders’ Nomination Board | 05-Nov-2024 | 07:00 | RNS |
Faron’s Capital Markets Day 2024 | 22-Oct-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 207.50p |
Change Today | -7.50p |
% Change | -3.49 % |
52 Week High | 262.50 |
52 Week Low | 126.50 |
Volume | 5,853 |
Shares Issued | 116.95m |
Market Cap | £242.68m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 2 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 1 |
Total | 5 |
No dividends found |
Time | Volume / Share Price |
16:27 | 1,000 @ 202.55p |
16:26 | 91 @ 209.00p |
16:12 | 1,000 @ 202.50p |
16:07 | 750 @ 205.00p |
13:23 | 750 @ 210.00p |
CFO | Yrjö E K Wichmann |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research